In vitro evaluation of voriconazole against some clinically important fungi.
作者： M R McGinnis , L Pasarell , D A Sutton , A W Fothergill , C R Cooper
关键词: Fluconazole 、 Amphotericin B 、 Amphotéricine B 、 In vitro 、 Voriconazole 、 Pharmacology 、 Dimorphic fungus 、 Microbiology 、 Amfotericina B 、 Itraconazole 、 Biology
摘要: Voriconazole was compared to amphotericin B, fluconazole, and itraconazole by using an in vitro macrobroth dilution test based upon current National Committee for Clinical Laboratory Standards tentative standards against the dimorphic fungi several opportunistic molds yeasts. In all instances, voriconazole MICs were lower than those of fluconazole. most recorded B itraconazole.
sci-hub.se 参考文章(8)
Victor Lorian, Antibiotics in laboratory medicine Published in <b>2005</b> in Philadelphia by Lippincott Williams & Wilkins. ,(2005)
Erika Bruck, National Committee for Clinical Laboratory Standards. Pediatrics. ,vol. 65, pp. 187- 188 ,(1980)
A L Barry, S D Brown, In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrobial Agents and Chemotherapy. ,vol. 40, pp. 1948- 1949 ,(1996) , 10.1128/AAC.40.8.1948
D George, P Miniter, V T Andriole, Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrobial Agents and Chemotherapy. ,vol. 40, pp. 86- 91 ,(1996) , 10.1128/AAC.40.1.86
M V Martin, J Yates, C A Hitchcock, Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs Antimicrobial Agents and Chemotherapy. ,vol. 41, pp. 13- 16 ,(1997) , 10.1128/AAC.41.1.13
J. H. Rex, M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, A. L. Barry, , Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections Clinical Infectious Diseases. ,vol. 24, pp. 235- 249 ,(1997) , 10.1093/CLINIDS/24.2.235
M Murphy, E M Bernard, T Ishimaru, D Armstrong, Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy. ,vol. 41, pp. 696- 698 ,(1997) , 10.1128/AAC.41.3.696
S A Radford, E M Johnson, D W Warnock, In Vitro Studies of Activity of Voriconazole (UK-109,496), a New Triazole Antifungal Agent, against Emerging and Less-Common Mold Pathogens Antimicrobial Agents and Chemotherapy. ,vol. 41, pp. 841- 843 ,(1997) , 10.1128/AAC.41.4.841